We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
The drive for high-quality packaging has helped manufacturers focus on increasing consistency of performance in devices such as auto-injector and patch injection systems. In addition, there is an increased focus on providing drug delivery systems that are easy to use. A consistent quality of components can help to improve performance and ensure delivery in the home environment, while user-centric systems can help assist with compliance.
Systems that enable patients to control the rate of the dose, offer options for those with dexterity challenges and provide an easy-to-use option for home injection are ideal for home use. West’s SelfDose® injection system technology platform* is provided by West to the pharmaceutical partner to be combined with their specific drug product packaged in a 1mL long prefilled syringe. The system has been designed as a two-step operation where the patient simply removes the cap and presses the system against the skin to deliver a subcutaneous injection. Audible, visual and tactile end-of-dose indicators, as well as a passive safety system that covers the needle after injection, ease the drug delivery process for patients with dexterity challenges.
Patient-activated and controlled systems like the SelfDose system assist with compliance since the systems are not indicative of a syringe injection, which may be less frightening for the patient. Thus compliance may be easier and the therapy more successful for those with needle phobias. In addition, the patient can self-inject, which offers the possibility of alternative dose frequencies to help aid with comfort and preference. In addition, patient-activated and controlled systems do not rely on complicated mechanics (spring activation, etc.), which can help to shorten the development time needed to pair the device with a drug.
For more information about SelfDose, click here.
SelfDose™ is a trademark of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions.
The health and safety of our team members has always been West’s top priority. This mindset is supported by our Board of Directors and is led by our President and CEO, Eric Green, who often reiterates his belief that “one incident is one too many.”
The idea of establishing a rubber manufacturing company was born during a visit by the purchasing manager of the penicillin factory, Chemie Grunenthal in Stolberg. He asked whether I could produce rubber stoppers for penicillin bottles. I did some research and realized rubber stoppers were needed for lots of different types of medicine and there wasn’t currently a company specializing in this field.
Critical quality attributes (CQAs) of biologic drug products can be affected by multiple factors throughout the product lifecycle, including the container closure and delivery systems. Diane Paskiet, Director of Scientific Affairs at West Pharmaceutical Services, discussed containment and delivery system compatibility with biologic drug products along with regulatory considerations in her presentation Establishing Safety of Container Closure and Delivery Device Systems at the PepTalk 2017 conference. Evaluating potential impacts early, holistically, and throughout bioprocessing can facilitate decisions at each step that will minimize risks to CQAs and safety.
As the adoption and acceptance of self-administered therapies grows, patients are spending less time with physicians and are playing a greater role in the delivery and management of their treatments. With the growing demand for extended-release and high-concentration formulations, more drug delivery systems choices are now available to differentiate drug products in a crowded market. Patient preferences can drive the selection of self-injection systems for a drug therapy. Selecting a system that patients prefer can, simplify use and increase compliance with the dosage regimen.
<p><em>A scientific poster by: Clara Goodfield, Eugene Polini, Amy Miller and Wayne Curry</em></p><p><em>The ideal sterilization process destroys all microorganisms rapidly with minimal adverse impact on the chemical and physical properties of the elastomeric closure. Developing and validating an acceptable sterilization process is critical to the drug product quality. This study served to help understand the potential deterioration of physical and chemical properties, the possible impact to functionality and the potential changes to the extractable/leachable profile as a result of sterilization</em></p>
English
Chinese
